Myriad Genetics' MyPlan(TM) Lung Cancer Test Meets Primary Clinical Endpoint

SALT LAKE CITY, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced new data published in Clinical Cancer Research that showed the myPlan Lung Cancer test is a significant predictor of lung cancer death in patients with early-stage, resectable lung adenocarcinoma and may be a valuable tool for selecting which early-stage patients should be considered for additional post-surgical chemotherapy.

"Lung cancer remains one of the most difficult-to-treat cancers. New prognostic markers to guide treatment decisions in early-stage, non-small cell lung cancer are necessary to improve outcomes for patients," said Edward S. Kim, M.D., co-author and chair of the Department of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, Charlotte NC. "In this verification study, the 31-gene cell cycle progression score was demonstrated to be a significant prognostic marker in resectable lung adenocarcinoma in that it stratifies patients' risk more effectively than conventional clinical parameters. This new information will further improve our ability to define the most appropriate treatment plan for surgically-treated, lung-cancer patients."

The purpose of this study was to investigate the significance of the myPlan Lung Cancer test as a predictor of survival in patients with early-stage lung adenocarcinoma in three independent data sets. The primary endpoint was overall survival as measured by disease related death within five years of surgery. Additionally, the study assessed the prognostic value of the score as compared to the conventional clinical variables of disease progression including age, stage of disease, gender, smoking status and tumor size. 

The myPlan Lung Cancer test measured mRNA expression levels of 31 cell cycle proliferation genes and 15 housekeeping genes in stage I and II tumor samples from a total of 841 patients. The results showed that myPlan Lung Cancer consistently was the strongest independent predictor of 5-year disease survival and remained the dominant prognostic marker in the presence of conventional clinical variables. 

If you liked this article you might like

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Bullish and Bearish Reversals in the Market

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments